The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?

The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals.

NCT04322786•University College, London

View on ClinicalTrials.gov

Summary

The study use UK based linked electronic health records from the Clinical Research Datalink (CALIBER) of 5.6 million individuals to conduct a matched case-control study to investigate the incidence of influenza in individuals prescribed ACEI compared to those not prescribed ACEI.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•We identify individuals aged 18 years or older and registered in the current primary care practice for at least one year.

Exclusion Criteria

•We exclude individuals with a prior history of influenza and viral pneumonia before study entry.

Key Dates

Start Date

January 1, 1998

Primary Completion Date

May 31, 2016

Completion Date

March 31, 2021

Last Updated

November 13, 2020

Enrollment

1,302,508

ACTUAL participants

Conditions

Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom

Interventions

ACE inhibitor

DRUG